Fundies. English
Segment disclosures
Company overviewQUIDEL CORP /DE/
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
14 dimension combinations 70 retained observations 12 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Triage Business · Molecular
Business Acquisition · Statement Business Segments
Source dimensions
us-gaap:BusinessAcquisitionAxis=qdel:TriageBusinessMember;us-gaap:StatementBusinessSegmentsAxis=qdel:MolecularMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 47030000 | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
Cardiac Immunoassay
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:CardiacImmunoassayMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 255788000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 242933000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 266505000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 266524000 | USD | 2021-02-18 · 23:16:06.000Z | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 47030000 | USD | 2020-02-13 · 22:02:26.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 0 | USD | 2019-02-15 · 21:18:17.000Z | Open filing evidence |
Gastrointestinal Disease
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:GastrointestinalDiseaseMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-12-31 | 7224000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 7414000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 6622000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 6328000 | USD | 2015-02-24 · 01:22:52.000Z | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 6920000 | USD | 20140227 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 5967000 | USD | 20130222 | Open filing evidence |
Immunoassays
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:ImmunoassaysMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 1197459000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 1144831000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 191736000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 183160000 | USD | 2021-02-18 · 23:16:06.000Z | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 165099000 | USD | 2020-02-13 · 22:02:26.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 121416000 | USD | 2019-02-15 · 21:18:17.000Z | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 130348000 | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 118715000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
Infectious Disease
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:InfectiousDiseaseMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-12-31 | 141857000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 130416000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 128079000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 110982000 | USD | 2015-02-24 · 01:22:52.000Z | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 112227000 | USD | 20140227 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 68869000 | USD | 20130222 | Open filing evidence |
License Fees And Royalties
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:LicenseFeesAndRoyaltiesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-12-31 | 6189000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 7681000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 3917000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 2452000 | USD | 2015-02-24 · 01:22:52.000Z | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 2419000 | USD | 20140227 | Open filing evidence |
Molecular Diagnostic Solutions
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:MolecularDiagnosticSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 200487000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 222964000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 21716000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 19358000 | USD | 2021-02-18 · 23:16:06.000Z | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 13636000 | USD | 2020-02-13 · 22:02:26.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 9506000 | USD | 2019-02-15 · 21:18:17.000Z | Open filing evidence |
Molecular
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:MolecularMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2016-01-01 – 2016-12-31 | 0 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 0 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 3418000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
Other Disease
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:OtherDiseaseMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-12-31 | 3698000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 4315000 Restated | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 5379000 Restated | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 3326000 | USD | 2015-02-24 · 01:22:52.000Z | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 4322000 Restated | USD | 20140227 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 3864000 | USD | 20130222 | Open filing evidence |
Royaltiesgrantsandother
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:RoyaltiesgrantsandotherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2016-01-01 – 2016-12-31 | 11211000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 7609000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 9475000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
Specialized Diagnostic Solutions
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:SpecializedDiagnosticSolutionsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 44817000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 50940000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2019-01-01 – 2019-12-31 | 54933000 | USD | 2022-02-18 · 01:05:16.000Z | Open filing evidence |
| 2018-01-01 – 2018-12-31 | 53243000 | USD | 2021-02-18 · 23:16:06.000Z | Open filing evidence |
| 2017-01-01 – 2017-12-31 | 51978000 | USD | 2020-02-13 · 22:02:26.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 60681000 | USD | 2019-02-15 · 21:18:17.000Z | Open filing evidence |
Specialtyproducts
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:SpecialtyproductsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 13636000 | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 9506000 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 5423000 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 7779000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
Virology
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:VirologyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2017-01-01 – 2017-12-31 | 51978000 | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2016-01-01 – 2016-12-31 | 60681000 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2015-01-01 – 2015-12-31 | 60358000 Restated | USD | 2018-02-27 · 22:20:41.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 44771000 | USD | 2017-02-16 · 22:12:13.000Z | Open filing evidence |
Women Health
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=qdel:WomenHealthMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-12-31 | 37161000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 34332000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 33328000 | USD | 2016-02-23 · 00:28:14.000Z | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 32653000 | USD | 2015-02-24 · 01:22:52.000Z | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 32715000 | USD | 20140227 | Open filing evidence |
| 2010-01-01 – 2010-12-31 | 32246000 | USD | 20130222 | Open filing evidence |